194 related articles for article (PubMed ID: 11516786)
1. Immunostimulating complexes (ISCOMs) for nasal vaccination.
Hu KF; Lövgren-Bengtsson K; Morein B
Adv Drug Deliv Rev; 2001 Sep; 51(1-3):149-59. PubMed ID: 11516786
[TBL] [Abstract][Full Text] [Related]
2. Iscom and iscom-matrix enhance by intranasal route the IgA responses to OVA and rCTB in local and remote mucosal secretions.
Ekström J; Hu KF; Bengtsson KL; Morein B
Vaccine; 1999 Jun; 17(20-21):2690-701. PubMed ID: 10418920
[TBL] [Abstract][Full Text] [Related]
3. The immunostimulating complex (ISCOM) is an efficient mucosal delivery system for respiratory syncytial virus (RSV) envelope antigens inducing high local and systemic antibody responses.
Hu KF; Elvander M; Merza M; Akerblom L; Brandenburg A; Morein B
Clin Exp Immunol; 1998 Aug; 113(2):235-43. PubMed ID: 9717973
[TBL] [Abstract][Full Text] [Related]
4. Functional aspects of iscoms.
Morein F; Bengtsson KL
Immunol Cell Biol; 1998 Aug; 76(4):295-9. PubMed ID: 9723770
[TBL] [Abstract][Full Text] [Related]
5. Induction of antibody responses in the common mucosal immune system by respiratory syncytical virus immunostimulating complexes.
Hu KF; Ekström J; Merza M; Lövgren-Bengtsson K; Morein B
Med Microbiol Immunol; 1999 May; 187(4):191-8. PubMed ID: 10363675
[TBL] [Abstract][Full Text] [Related]
6. Current status and potential application of ISCOMs in veterinary medicine.
Morein B; Hu KF; Abusugra I
Adv Drug Deliv Rev; 2004 Jun; 56(10):1367-82. PubMed ID: 15191787
[TBL] [Abstract][Full Text] [Related]
7. From toxin to adjuvant: the rational design of a vaccine adjuvant vector, CTA1-DD/ISCOM.
Lycke N
Cell Microbiol; 2004 Jan; 6(1):23-32. PubMed ID: 14678328
[TBL] [Abstract][Full Text] [Related]
8. The mucosal adjuvant effects of cholera toxin and immune-stimulating complexes differ in their requirement for IL-12, indicating different pathways of action.
Grdic D; Smith R; Donachie A; Kjerrulf M; Hörnquist E; Mowat A; Lycke N
Eur J Immunol; 1999 Jun; 29(6):1774-84. PubMed ID: 10382739
[TBL] [Abstract][Full Text] [Related]
9. The combined CTA1-DD/ISCOM adjuvant vector promotes priming of mucosal and systemic immunity to incorporated antigens by specific targeting of B cells.
Helgeby A; Robson NC; Donachie AM; Beackock-Sharp H; Lövgren K; Schön K; Mowat A; Lycke NY
J Immunol; 2006 Mar; 176(6):3697-706. PubMed ID: 16517738
[TBL] [Abstract][Full Text] [Related]
10. Intranasal immunisation with influenza-ISCOM induces strong mucosal as well as systemic antibody and cytotoxic T-lymphocyte responses.
Sjölander S; Drane D; Davis R; Beezum L; Pearse M; Cox J
Vaccine; 2001 Jul; 19(28-29):4072-80. PubMed ID: 11427284
[TBL] [Abstract][Full Text] [Related]
11. Immunomodulation by iscoms, immune stimulating complexes.
Morein B; Bengtsson KL
Methods; 1999 Sep; 19(1):94-102. PubMed ID: 10525444
[TBL] [Abstract][Full Text] [Related]
12. Iscom is an efficient mucosal delivery system for Mycoplasma mycoides subsp. mycoides (MmmSC) antigens inducing high mucosal and systemic antibody responses.
Abusugra I; Morein B
FEMS Immunol Med Microbiol; 1999 Jan; 23(1):5-12. PubMed ID: 10030541
[TBL] [Abstract][Full Text] [Related]
13. Frequent nasal administrations of recombinant cholera toxin B subunit (rCTB)-containing tetanus and diphtheria toxoid vaccines induced antigen-specific serum and mucosal immune responses in the presence of anti-rCTB antibodies.
Yasuda Y; Isaka M; Taniguchi T; Zhao Y; Matano K; Matsui H; Morokuma K; Maeyama J; Ohkuma K; Goto N; Tochikubo K
Vaccine; 2003 Jun; 21(21-22):2954-63. PubMed ID: 12798639
[TBL] [Abstract][Full Text] [Related]
14. Comparison of intranasal with targeted lymph node immunization using PR8-Flu ISCOM adjuvanted HIV antigens in macaques.
Koopman G; Bogers WM; van Gils M; Koornstra W; Barnett S; Morein B; Lehner T; Heeney JL
J Med Virol; 2007 May; 79(5):474-82. PubMed ID: 17385685
[TBL] [Abstract][Full Text] [Related]
15. A novel non-toxic combined CTA1-DD and ISCOMS adjuvant vector for effective mucosal immunization against influenza virus.
Eliasson DG; Helgeby A; Schön K; Nygren C; El-Bakkouri K; Fiers W; Saelens X; Lövgren KB; Nyström I; Lycke NY
Vaccine; 2011 May; 29(23):3951-61. PubMed ID: 21481325
[TBL] [Abstract][Full Text] [Related]
16. Protective effect of nasal immunization of influenza virus hemagglutinin with recombinant cholera toxin B subunit as a mucosal adjuvant in mice.
Isaka M; Zhao Y; Nobusawa E; Nakajima S; Nakajima K; Yasuda Y; Matsui H; Hasegawa T; Maeyama J; Morokuma K; Ohkuma K; Tochikubo K
Microbiol Immunol; 2008 Feb; 52(2):55-63. PubMed ID: 18380802
[TBL] [Abstract][Full Text] [Related]
17. CTA1-DD-immune stimulating complexes: a novel, rationally designed combined mucosal vaccine adjuvant effective with nanogram doses of antigen.
Mowat AM; Donachie AM; Jägewall S; Schön K; Löwenadler B; Dalsgaard K; Kaastrup P; Lycke N
J Immunol; 2001 Sep; 167(6):3398-405. PubMed ID: 11544331
[TBL] [Abstract][Full Text] [Related]
18. Mucosal and systemic antibody responses against an acellular pertussis vaccine in mice after intranasal co-administration with recombinant cholera toxin B subunit as an adjuvant.
Isaka M; Yasuda Y; Taniguchi T; Kozuka S; Matano K; Maeyama J; Morokuma K; Ohkuma K; Goto N; Tochikubo K
Vaccine; 2003 Mar; 21(11-12):1165-73. PubMed ID: 12559794
[TBL] [Abstract][Full Text] [Related]
19. A mucosal IgA response, but no systemic antibody response, is evoked by intranasal immunisation of dogs with Echinococcus granulosus surface antigens iscoms.
Carol H; Nieto A
Vet Immunol Immunopathol; 1998 Sep; 65(1):29-41. PubMed ID: 9802574
[TBL] [Abstract][Full Text] [Related]
20. Chimeric plant virus particles administered nasally or orally induce systemic and mucosal immune responses in mice.
Brennan FR; Bellaby T; Helliwell SM; Jones TD; Kamstrup S; Dalsgaard K; Flock JI; Hamilton WD
J Virol; 1999 Feb; 73(2):930-8. PubMed ID: 9882293
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
